Kornimate/medical-research-clean huggingface dataset:
impact on postoperative pain of three single-use adult supraglottic airway devices in short general anesthetic under controlled ventilation

Conditions: Pharyngolaryngeal Postoperative Pain

Summary: the investigators hypothesize that incidence of pharyngolaryngeal postoperative pain caused by the i-gel and lma-suprême devices will be ≤ 5%


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * adult patients \> 18 * asa score i-iii * patient scheduled to undergo elective surgery lasting less than two hours under general anaesthetic without tracheal intubation * the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study * the subject refuses to sign the consent * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * the patient is pregnant or breastfeeding * emergency surgery * sore thoat ≤ 1 month * risk of aspiration of gastric contents * body mass index (bmi) \> 35 * patients with expected airway difficulties * contra-indication for any of the devices (symptomatic hiatal hernias, pathological obesity, poly trauma or serious injury, delayed gastric emptying, use of opiates during fasting) * patients who are not fasting for routine and emergency anesthesia * trismus, limited mouth opening, abscess or pharyngoperilaryngeal mass
circulating tumor dna as surgical biomarker in patients with pancreatic adenocarcinoma for statement of resectability

Conditions: PDAC - Pancreatic Ductal Adenocarcinoma

Summary: the main objective is the evaluation of the prognostic value of ctdna (circulating tumor dna) as a marker of surgical futility in patients with operable pdac.

in the era of personalized medicine and treatments guided by tumor biology, no specific tumor marker has real prognostic value. this is the reason why the search for a specific marker through a noninvasive blood test that can give indications on the usefulness of the resectability of pancreatic adenocarcinoma would be very valuable. our project proposes the evaluation of ctdna during various treatment courses of patients with pdac in order to evaluate its efficacy as a prognostic and predictive marker of response to treatment.

Eligibility criteria:
inclusion criteria: 1. patients with pdac with indication to surgical resection, including those undergoing upfront surgery or surgery following induction treatment. non resectable patient defined as a patient with surgical indication at standard preoperative clinical, biological and morphological evaluation, but eventually not resected because of advanced disease or contraindications revealed during surgical exploration will be excluded 2. non-metastatic status confirmed by an abdomen ct-scan (as our routine clinical practice). 3. patients able to give a specific informed consent. 4. age ≥ 18 years. exclusion criteria: 1. non resectable patient defined as a patient with surgical indication at standard preoperative clinical, biological and morphological evaluation, but eventually not resected because of advanced disease or contraindications revealed during surgical exploration will be excluded (drop-out) 2. non-controlled congestive heart failure. 3. non-treated angina. 4. recent myocardial infarction (in the previous year). 5. non-controlled aht (sbp \>160 mm or dbp \> 100 mm, despite optimal drug treatment). 6. long qt. 7. major non-controlled infection. 8. severe liver failure. 9. age \< 18 years. 10. informed consent not signed. 11. pregnant or breastfeeding women and women of child-bearing age not using effective means of contraception.

Keywords: biomarker
my research legacy pilot study

Conditions: Myocardial Infarction; Stroke; Cardiomyopathy, Dilated; Systolic Heart Failure; Atrial Fibrillation; Aortic Dissection

Summary: the my research legacy pilot study will establish a participant registry that collects self-reported health data and answers to online survey questions about individual daily choices, diets, and exercise; data from wearable devices; and, (optional) data from genome sequencing analysis. individuals under the age of 50 who meet eligibility criteria will answer questions using the american heart association's (aha) life's simple 7™ my life check v4.0 three times over the course of 6 months and transmit data from a fitbit charge 2 device. all other individuals who are interested in the study and meet entry criteria may also enroll.

2,000 participant my research legacy pilot study 1. day 0 - enroll online, complete aha's life's simple 7™ survey prospective participants will enroll in the research initiative via the my research legacy website (myresearchlegacy.org). they will go through an online process in which they will answer brief, pre-qualifying questions before consenting to participate in the study. * participants will attest to their age and us residence, and will provide a self-reported diagnosis of cardiovascular disease (myocardial infarction, atrial fibrillation, aortic dissection, systolic congestive heart failure/cardiomyopathy) and/or stroke. * eligible participants will read and sign an online consent form. * within the participant console, the participants will answer aha's life's simple 7™ my life check v4.0 assessment. * participants will be asked during the consent process if they will consent to provide medical records relevant to their diagnosis. 2. day 90 complete aha's life's simple 7™ my life check v4.0 assessment; start transmission from the fitbit charge 2. 3. online survey and contact day 180 after enrollment, participants will receive an email requesting that they visit the participant console to repeat aha's life's simple 7™ my life check v4.0 survey. participants also have the option of determining whether or not they want to be contacted for future studies.

Eligibility criteria:
inclusion criteria: 1. age \> or = to 18 years but \< 50 years. 2. history of one (or more) of the following: 1. myocardial infarction 2. stroke 3. aortic dissection 4. systolic heart failure/cardiomyopathy 5. atrial fibrillation 3. individuals of any age \> or = 18 years who don't have above medical conditions but want to participate in the study. 4. access to a computer and/or cell phone with internet access. exclusion criteria: 1. unwillingness to sign informed consent 2. no access to a computer and/or cell phone with internet access.

Keywords: myocardial infarction stroke dilated cardiomyopathy systolic heart failure atrial fibrillation aortic dissection wearable devices genomic sequencing
evaluation of biological markers of mesenteric ischemia during an ultra-trail

Conditions: Ultra-trail Participation

Summary: to assess the evolution of biological markers of mesenteric ischemia during ultratrail.

during physical exercise, increased sympathetic nervous system activity redistributes blood flow from splanchnic organs to working muscles. with prolonged duration and / or intensity, the splanchnic blood flow can be reduced by 80% or more. a severely reduced of splanchnic blood flow can frequently cause gastrointestinal ischemia. this ischemia associated with reduced vagal activity probably results in changes in motility and absorption. high symptoms are reported in 40% of runners with reflux and heartburn in 15-20% of runners. the low symptoms have an incidence of about 70% in the long runs type ultra-trail. biological markers such as i-fabp have been shown to be useful in the diagnosis of mesenteric ischemia.

Eligibility criteria:
inclusion criteria: * healthy voluntary subject * age \> 18 years * written consent * subject affiliated to social security * medical certificate (mandatory to take part in the ultra-trail) exclusion criteria: * refusal to participate * subject with legal protection (guardianship, trusteeship)

Keywords: biological markers mesenteric ischemia ultratrail
efficacy of a single dose of aspirin vs. acetaminophen in tension type headache

Conditions: Headache

Summary: the purpose of this trial is to determine if a single, oral dose of a fast release aspirin 1000 mg provides relief compared to acetaminophen 1000 mg and placebo in subjects with tension-type headache pain.


Eligibility criteria:
inclusion criteria: * healthy, ambulatory, male and female volunteers ages 18-65 years old * history of an onset of tension type headaches before age 50 * experiencing over the last year ≥ 4 tension type headaches of at least moderate intensity per month and with the majority of headaches lasting greater than three hours, that meet commonly recognized criteria for diagnosis per the international headache society * history of response to treatment with over-the-counter (otc) analgesics * understand the pain rating scales (as judged by the trial coordinator) * present with at least moderate headache pain on a 0-10 point numerical rating scale (a score of at least 4 on an 11 point scale ranging from 0 to 10) at the treatment visit * onset of pain within three hours of the treatment visit * confirmation by a physician of acute tension type headache symptoms as described by the international headache society diagnostic criteria exclusion criteria: * history of hypersensitivity to aspirin, salicylates, other nsaids, acetaminophen, and similar pharmacological agents or components of the investigational products, including the placebo * use of any immediate release analgesic/anti-pyretic within four hours or use of any sustained release or long acting analgesic/anti-pyretic within 12 hours proceeding administration of investigational product * presence of symptoms that are consistent with menstrual headache or migraine headache as described by the international headache society diagnostic criteria * history of migraine headaches more than once per month * relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the trial in the judgment of the investigator * current or past history of bleeding disorder(s) * history of gastrointestinal bleeding or perforation, related to previous nonsteroidal anti-inflammatory drugs (nsaid) therapy. active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding) * recent head or neck trauma (within 2 weeks) * current use of blood thinning (anticoagulant), low dose aspirin, or steroid drug
study to evaluate multiple ascending dose and multi-dose of dt-216 in adult patients with friedreich ataxia

Conditions: Friedreich Ataxia

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of multiple doses of intravenous dt-216 in adult patients with friedrich ataxia.


Eligibility criteria:
inclusion criteria: * genetically confirmed diagnosis of friedreich ataxia with homozygous gaa repeat expansions. * able and willing to sign informed consent form prior to study enrollment. * stage 5.5 or less on the functional staging for ataxia (fsa) at screening. exclusion criteria: * has any concomitant medical condition that in the opinion of the investigator, puts the participant at risk or precludes participant from completing the study. * has clinically significant abnormal laboratory results. * has significant cardiac disease. * received an investigational drug within 3 months of screening.
ecg changes in children and adolescents with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: diabetes mellitus type 1 is characterized by an absolute insulin deficiency caused by t-cell-mediated autoimmune destruction of pancreatic β-cells . it is the predominant form of diabetes mellitus during childhood and adolescence. hyperglycemia is a major cause of vascular and neuropathic complications that are seen in patients with diabetes mellitus type 1.

cardiovascular risk factors remain the most controversial chronic complication in diabetes mellitus type 1 neuropathy in diabetes mellitus type 1 can lead to abnormalities in the response of the coronary vasculature to sympathetic stimulation, which may manifest clinically as resting tachycardia or bradycardia, exercise intolerance, orthostatic hypotension, loss of the nocturnal decline in blood pressure, or silent myocardial ischemia on cardiac testing. these abnormalities can lead to delayed presentation of cardiovascular disease. an early indicator of cardiac autonomic neuropathy is reduced heart rate variability, which can be assessed qualitatively in the clinic. limited data suggest silent myocardial ischemia is more common in the presence of cardiac autonomic neuropathy . cardiovascular mortality is a leading cause of death in type 1 diabetic patients, in particular in patients with nephropathy.qt dispersion defined as the difference between maximal and minimal qt intervals from different electrocardiogram leads ( the qt interval was defined as the time between the first deflection from the isoelectric pr interval and the visual return of the t wave to the t-p segment ) ,because these electrocardiogram abnormalities may confer an increased risk of ventricular arrhythmias and sudden cardiac death , early identification may have prognostic value .

Eligibility criteria:
inclusion criteria: * all children and adolescents with type 1 diabetes exclusion criteria: 1. cornary artery disease . 2. heart failure , congenital heart disease , 3. rheumatic valve disease . 4. primary cardiomyopathy . 5. thyroid dysfunction . 6. bundle branch block and atrioventricular conduction abnormalities . 7. anti arrhythmic drugs .
motor and cognitive dual-task gait training effect functional outcome in intellectual disability

Conditions: Intellectual Disability

Summary: to find out the comparative effects of motor and cognitive dual gait training on improving the balance control and mobility skills among intellectual disable patients.

previous studies had done a lot of work in improving balance and mobility skills by combining both motor and cognitive dual gait training (cdt and mdt) techniques among down syndrome, parkinsonism and so on but not a single study was conducted in order to determine the comparative effects of cdt and mdt especially in intellectual disability individuals to improve balance so the study was conducted in order to find the comparative effect for the better understanding of the treatment effects.

Eligibility criteria:
inclusion criteria: * both genders having iq range between 50-69 * walk without assistive devices * having a grade i-iv on the rlacfs exclusion criteria: * genetic disorders (down syndrome). * age-related diseases like parkinsonism and alzheimer disease. * cerebrovascular accident, dementia, cerebral palsy * severe visual impairment. * medications (sedatives or narcotics)

Keywords: motor and cognitive dual task gait training
pet/mri in pah patients

Conditions: Pulmonary Arterial Hypertension

Summary: aim of the study is to compare novel parameters of right ventricle (rv) function from right heart catheterization (rhc) and magnetic resonance imaging (mri) with pet-derived rv fdg uptake.

objectives in pilot study investigators aimed to compare novel parameters of right ventricle (rv) function from right heart catheterization (rhc) and magnetic resonance imaging (mri) with pet-derived rv fdg uptake. background right ventricular (rv) function is a major determinant of survival in patients with pulmonary arterial hypertension (pah). hemodynamic parameters like end-systolic elastance (ees), arterial elastance (ea), pulmonary arterial compliance (pac) and ees/ea ratio have been shown to reflect rv function and prognosis in pah. increased rv 18f-fluoro-2-deoxyglucose (fdg) uptake in positron emission tomography (pet) was recently associated with progressive rv dysfunction in these patients. methods twenty-five stable pah patients (49.92±15.94 years) and twelve healthy subjects (control group, 44.75±13.51 years) had simultaneous pet and mri scans performed. fdg was used as a tracer and its uptake was presented as a standardized uptake value (suv) for both left (lv) and right ventricle.

Eligibility criteria:
inclusion criteria: - pah exclusion criteria: the exclusion criteria were the following: patients in iv who class, eisenmenger physiology, pah associated with prevalent systemic-to-pulmonary shunts due to moderate to large defects (according to european guidelines) \[16\], group ii, iii, iv, v of pulmonary hypertension, diabetes mellitus and contraindications to cardiac mri.
antiglucocorticoid therapy for cognitive impairment in late-life anxiety disorders

Conditions: Anxiety Disorders

Summary: this study seeks to develop and test a novel, mechanistic treatment for mitigating cognitive impairment in older adults with anxiety disorders. anxiety disorders are common, severe, and disabling in older adults. one particularly impairing aspect of late-life anxiety disorders is cognitive impairment: impairments in memory and executive function cause disability, impede treatment response to psychotherapy, may lead to dementia, and are not corrected by standard anti-anxiety treatments. this pilot study will test the glucocorticoid antagonist, mifepristone, for cognitive impairment in late-life anxiety disorders. mifepristone blocks the effects of elevated cortisol levels on glucocorticoid receptors in the brain; it has been studied preliminarily in various neuropsychiatric disorders, such as psychotic depression and bipolar disorder, with well-documented safety and tolerability.

currently, no treatment exists to address cognitive impairment in late-life anxiety disorders. in this study, fifteen patients aged 60+ with an anxiety disorder (current or in partial remission) and subjective and/or objective evidence of cognitive impairment will receive treatment with mifepristone. at the baseline visit participants will be randomized to receive either mifepristone 300mg or a placebo daily for 7 days. participants will be reassessed after 7 days (week 1 visit) of receiving study medication (mifepristone or placebo). at that time all participants will be provided mifepristone 300mg daily for the remaining 3 weeks of study treatment. the primary outcome measure will be neurocognition, as assessed by a battery of neuropsychological measures focusing on immediate and delayed memory and executive function (administered at baseline, week 1, week 4, and week 12). saliva samples for cortisol measurement will be collected immediately following the baseline visit and week 4 visit. secondary outcomes will be self-reported anxiety and depressive symptoms.

Eligibility criteria:
inclusion criteria: * age 65 and older * non-demented by clinical evaluation * current or partially remitted generalized anxiety disorder or panic disorder * currently taking antidepressant treatment with stable dose for at least 8 weeks * memory impairment exclusion criteria: * mild to severe dementia * diabetes * current alcohol or substance abuse * current or lifetime psychotic symptoms, bipolar disorder, or eating disorder * untreated endocrinologic disease * lifetime cushing's or addison's disease * current cancer * history of metastatic cancer * current use of systemic corticosteroids

Keywords: anxiety older adult memory cognitive saint louis treatment cognitive impariment
machine learning predict acute kidney injury in patients following cardiac surgery

Conditions: Machine Learning; Acute Kidney Injury

Summary: cardiac surgery-associated acute kidney injury (csa-aki) is a major complication which may result in adverse impact on short- and long-term mortality. the investigatorshere developed several prediction models based on machine learning technique to allow early identification of patients who at the high risk of unfavorable kidney outcomes. the retrospective study comprised 2108 consecutive patients who underwent cardiac surgery from january 2017 to december 2020.


Eligibility criteria:
inclusion criteria: * age over 18 years who underwent cardiac surgery exclusion criteria: * data miss greater than 10%
study of ontak® to treat cutaneous t-cell lymphoma (ctcl)

Conditions: Lymphoma, T-Cell, Cutaneous

Summary: the purpose of this research study is to evaluate how effective ontak is in the treatment of cutaneous t-cell lymphoma (ctcl) and determine whether the presence of a type of protein called cd25 on the cancer cells makes a difference in how the body responds to the treatment. the hypothesis is that there is no difference in response rate for patients whose tumor cells are cd25 positive or negative.


Eligibility criteria:
inclusion criteria: * persistent or recurrent cutaneous t-cell lymphoma (ctcl) stage ib-iva as defined by tnm staging. * pathologic proven diagnosis (cytologically confirmed) of ctcl documented in patient history. * preserved organ function: creatinine and/or liver function levels \<1.5 times institutional upper limits of normal (uln). * adequate liver function as indicated by bilirubin \< or equal to 1.5 times uln, alt \< or equal to 2 times uln, ast \< or equal to 2 times uln. * albumin \>3.0 g/dl * adequate renal function as indicated by scr \< or equal to 2.5 mg/dl. * ecog performance status between 0-2. * women of childbearing potential should be screened for pregnancy prior to treatment and utilize effective contraceptive methods (e.g. barrier) during treatment period. * patients over the age of 18 who are willing and able to provide informed consent. exclusion criteria: * pathology consistent with peripheral t-cell lymphoma. * stage ivb (visceral involvement with ctcl, other than lymph node involvement). * history of human immunodeficiency virus (hiv), hepatitis b or hepatitis c infection. * patients who are pregnant or breast feeding. * allergy to or have history of allergy to diphtheria toxin or il-2. * previous ontak® usage. * unstable cardiovascular disease. * patients who have received systemic or topical antineoplastic therapy or investigational medications within past 14 days. exception: clear evidence of disease progression requiring immediate intervention and in the absence of ongoing toxicity from prior therapy. * ongoing deep vein thrombosis or a diagnosis of deep vein thrombosis less than 3 months prior to protocol enrollment.

Keywords: cutaneous t-cell lymphoma ontak cd25